• Novocure announced published Phase 3 PANOVA-3 results in JAMA Network Open showing meaningful quality-of-life and pain benefits from Tumor Treating Fields therapy.
• The trial tested the device with gemcitabine and nab-paclitaxel as first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
• The combination improved overall survival compared with chemotherapy alone, meeting the trial’s primary endpoint.
• No new safety signals emerged; mild to moderate skin reactions were the most common device-related adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611131130BIZWIRE_USPR_____20261113_BW972844) on November 13, 2026, and is solely responsible for the information contained therein.